ArticleAntimicrobial resistance and infection control2019
Vancomycin-resistant enterococci (VRE) screening and isolation in the general medicine ward: a cost-effectiveness analysis.
Article in Antimicrobial resistance and infection control, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluation of GeneXpert vanA/vanB in the early diagnosis of vancomycin-resistant enterococci infection.PLoS neglected tropical diseases · 2021Pooled it
- A validated prediction model for intestinal vancomycin-resistant Enterococcus colonization in critically ill patients with sepsis: insights into risk stratification and clinical impact.BMC infectious diseases · 2026Article
- A Risk-Based Isolation Strategy for MDR-Endemic Facilities with Limited Resources.Infectious disease reports · 2026Review
- Dynamic screening strategies for the control of a prolonged vancomycin-resistant enterococci outbreak: A decade-long study in a Japanese tertiary hospital.Epidemiology and infection · 2026Article
- Existing Evidence from Economic Evaluations of Antimicrobial Resistance-A Systematic Literature Review.Antibiotics (Basel, Switzerland) · 2025Review
- Vancomycin-ResistantAntibiotics (Basel, Switzerland) · 2025Review
- AI modeling for outbreak prediction: A graph-neural-network approach for identifying vancomycin-resistant enterococcus carriers.PLOS digital health · 2025Article
- Multiplex Real-Time Polymerase Chain Reaction and Recombinase Polymerase Amplification: Methods for Quick and Cost-Effective Detection of Vancomycin-Resistant Enterococci (VRE).Antibiotics (Basel, Switzerland) · 2025Article
- Automated molecular detection of the vancomycin resistance genes vanA and vanB using the geneLEAD VIII platform.Access microbiology · 2025Article
- Vancomycin-Resistant Enterococci: Current Understandings of Resistance in Relation to Transmission and Preventive Strategies.Pathogens (Basel, Switzerland) · 2024Review
- Infection Prevention and Control Strategies According to the Type of Multidrug-Resistant Bacteria andAntibiotics (Basel, Switzerland) · 2024Review
- An Economic Evaluation Estimating the Clinical and Economic Burden of Increased Vancomycin-Resistant Enterococcus faecium Infection Incidence in Japan.Infectious diseases and therapy · 2023Article
- Comparison of Five Different Selective Agar for the Detection of Vancomycin-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Vancomycin-resistant Enterococcus faecium: should we screen on admission?APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2022Article
- A pre-pandemic COVID-19 assessment of the costs of prevention and control interventions for healthcare associated infections in medical and surgical wards in Québec.Antimicrobial resistance and infection control · 2021Observational
- Modeling the coronavirus disease 2019 pandemic: A comprehensive guide of infectious disease and decision-analytic models.Journal of clinical epidemiology · 2021Review
- Cost-effectiveness analysis of whole-genome sequencing during an outbreak of carbapenem-resistantAntimicrobial stewardship & healthcare epidemiology : ASHE · 2021Article
- Diabetic foot infections: Profile and antibiotic susceptibility patterns of bacterial isolates in a tertiary care hospital of Oman.Journal of education and health promotion · 2021Article
- Clonal distribution of vancomycin-resistant Enterococcus faecium in Turkey and the new singleton ST733.Journal of clinical laboratory analysis · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background: Vancomycin-resistant enterococci (VRE) are a serious antimicrobial resistant threat in the healthcare setting. We assessed the cost-effectiveness of VRE screening and isolation for patients at high-risk for colonisation on a general medicine ward compared to no VRE screening and isolation from the healthcare payer perspective. Methods: We developed a microsimulation model using local data and VRE literature, to simulate a 20-bed general medicine ward at a tertiary-care hospital with up to 1000 admissions, approximating 1 year. Primary outcomes were accrued over the patient's lifetime, discounted at 1.5%, and included expected health outcomes (VRE colonisations, VRE infections, VRE-related bacteremia, and deaths subsequent to VRE infection), quality-adjusted life years (QALYs), healthcare costs, and incremental cost-effectiveness ratio (ICER). Probabilistic sensitivity analysis (PSA) and scenario analyses were conducted to assess parameter uncertainty. Results: In our base-case analysis, VRE screening and isolation prevented six healthcare-associated VRE colonisations per 1000 admissions (6/1000), 0.6/1000 VRE-related infections, 0.2/1000 VRE-related bacteremia, and 0.1/1000 deaths subsequent to VRE infection. VRE screening and isolation accrued 0.0142 incremental QALYs at an incremental cost of $112, affording an ICER of $7850 per QALY. VRE screening and isolation practice was more likely to be cost-effective (> 50%) at a cost-effectiveness threshold of $50,000/QALY. Stochasticity (randomness) had a significant impact on the cost-effectiveness. Conclusion: VRE screening and isolation can be cost-effective in majority of model simulations at commonly used cost-effectiveness thresholds, and is likely economically attractive in general medicine settings. Our findings strengthen the understanding of VRE prevention strategies and are of importance to hospital program planners and infection prevention and control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.